346 research outputs found
Π Π°Π·ΡΠ°Π±ΠΎΡΠΊΠ° ΠΏΡΠΎΠ³ΡΠ°ΠΌΠΌΠ½ΠΎΠ³ΠΎ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ° Π΄Π»Ρ ΠΎΡΠ΅Π½ΠΊΠΈ ΠΈ ΡΠ΅Π°Π±ΠΈΠ»ΠΈΡΠ°ΡΠΈΠΈ Π΄Π²ΠΈΠ³Π°ΡΠ΅Π»ΡΠ½ΡΡ ΡΠ°ΡΡΡΡΠΎΠΉΡΡΠ² ΠΏΡΠΈ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΠΈ ΡΠ΅Π½ΡΡΠ°Π»ΡΠ½ΠΎΠΉ Π½Π΅ΡΠ²Π½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ
ΠΠ±ΡΠ΅ΠΊΡΠΎΠΌ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π² Π΄Π°Π½Π½ΠΎΠΉ ΡΠ°Π±ΠΎΡΠ΅ ΡΠ²Π»ΡΠ΅ΡΡΡ Π²Π»ΠΈΡΠ½ΠΈΠ΅ Π΄ΠΎΠΏΠΎΠ»Π½Π΅Π½Π½ΠΎΠΉ ΡΠ΅Π°Π»ΡΠ½ΠΎΡΡΠΈ Π½Π° Π΄Π²ΠΈΠ³Π°ΡΠ΅Π»ΡΠ½ΡΠ΅ ΡΠ°ΡΡΡΡΠΎΠΉΡΡΠ²Π° Π±ΠΎΠ»ΡΠ½ΠΎΠ³ΠΎ Ρ Π΄Π²ΠΈΠ³Π°ΡΠ΅Π»ΡΠ½ΠΎΠΉ Π΄ΠΈΡΡΡΠ½ΠΊΡΠΈΠ΅ΠΉ. Π¦Π΅Π»ΡΡ ΡΠ²Π»ΡΠ΅ΡΡΡ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠ° ΠΏΡΠΎΠ³ΡΠ°ΠΌΠΌΠ½ΠΎΠ³ΠΎ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ° Π΄Π»Ρ ΡΠ΅Π°Π±ΠΈΠ»ΠΈΡΠ°ΡΠΈΠΈ Π΄Π²ΠΈΠ³Π°ΡΠ΅Π»ΡΠ½ΡΡ
Π½Π°ΡΡΡΠ΅Π½ΠΈΠΉ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
. ΠΠΊΡΡΠ°Π»ΡΠ½ΠΎΡΡΡ ΡΠ°Π±ΠΎΡΡ Ρ ΡΠ²Π΅ΡΠ΅Π½Π½ΠΎΡΡΡΡ ΠΌΠΎΠΆΠ½ΠΎ Π½Π°Π·Π²Π°ΡΡ Π²ΡΡΠΎΠΊΠΎΠΉ, ΡΠ°ΠΊ ΠΊΠ°ΠΊ Π² Π½Π΅ΠΉ ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΡΡΡΡ ΠΏΠΎΡΠ»Π΅Π΄Π½ΠΈΠ΅ Π΄ΠΎΡΡΠΈΠΆΠ΅Π½ΠΈΡ ΠΊΠΈΠ±Π΅Ρ-ΠΈΠ½Π΄ΡΡΡΡΠΈΠΈ (ΠΎΡΠΊΠΈ Π΄ΠΎΠΏΠΎΠ»Π½Π΅Π½Π½ΠΎΠΉ ΡΠ΅Π°Π»ΡΠ½ΠΎΡΡΠΈ, ΠΈΠ½ΡΡΠ°ΠΊΡΠ°ΡΠ½ΡΠΉ Π΄Π°ΡΡΠΈΠΊ Π΄Π²ΠΈΠΆΠ΅Π½ΠΈΡ), ΡΠ°ΠΊΠΆΠ΅ ΡΠ°Π±ΠΎΡΠ° ΠΌΠΎΠΆΠ΅Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°ΡΡΡΡ Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ Π±Π°Π·Ρ Π΄Π»Ρ Π΄ΡΡΠ³ΠΈΡ
ΠΏΡΠΎΠ³ΡΠ°ΠΌΠΌ. ΠΠ±Π»Π°ΡΡΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π² ΠΌΠ΅Π΄ΠΈΡΠΈΠ½Π΅ ΡΠ²Π»ΡΠ΅ΡΡΡ - ΠΎΠ±Π»Π°ΡΡΡ Π½Π΅Π²ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ. ΠΠ΅Π΄ΠΈΡΠΈΠ½Π° ΠΎΠ΄Π½Π° ΠΈΠ· ΡΠ°ΠΌΡΡ
Π°ΠΊΡΡΠ°Π»ΡΠ½ΡΡ
ΡΠ°ΡΡΠ΅ΠΉ ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΡΡΠ²Π° Π² ΠΌΠΈΡΠ΅ Π³Π΄Π΅ Π²ΡΠ΅Π³Π΄Π° ΡΡΠ΅Π±ΡΡΡΡΡ ΡΠ»ΡΡΡΠ΅Π½ΠΈΡ ΠΈ ΠΏΡΠΈΠ²Π΅ΡΡΡΠ²ΡΠ΅ΡΡΡ Π½ΠΎΠ²Π°ΡΠΎΡΡΡΠ²ΠΎ Π΄Π»Ρ ΡΠ°ΡΡΠΈΡΠ΅Π½ΠΈΡ Π³ΡΠ°Π½ΠΈΡ Π²ΠΎΡΠΏΡΠΈΡΡΠΈΡ.The object of the study in this work is the effect of extended reality on the motor disorders of a patient with motor dysfunction. The goal is to develop a software package for the rehabilitation of motor disorders in patients. The relevance of work with confidence can be called high, because it uses the latest achievements of the cyber industry (glasses augmented reality, infrared motion sensor), and the work can also be used as a basis for other programs. The field of application in medicine is the field of neurology. Medicine is one of the most important parts of production in the world, where improvements are always required, and innovations are encouraged to expand the boundaries of perceptio
ΠΠΠΠΠ‘Π’ΠΠ― ΠΠΠ ΠΠΠΠΠ ΠΠΠΠΠ ΠΠ₯ΠΠΠ‘Π¬ΠΠΠ₯
Π£ 2009 Ρ. Π²ΠΈΠΏΠΎΠ²Π½ΡΡΡΡΡΡ 110 ΡΠΎΠΊΡΠ² Π²ΡΠ΄ Π·Π°ΡΠ½ΡΠ²Π°Π½Π½Ρ Ρ ΠΌΡΡΡΡ ΠΠ°ΡΠ΅ΡΠΈΠ½ΠΎΡΠ»Π°Π²Ρ Π²ΠΈΡΠΎΠ³ΠΎ Π³ΡΡΠ½ΠΈΡΠΎΠ³ΠΎ Π½Π°Π²ΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ Π·Π°ΠΊΠ»Π°Π΄Ρ, ΡΠΊΠΈΠΉ ΡΡΠΎΠ³ΠΎΠ΄Π½Ρ Π½Π°Π·ΠΈΠ²Π°ΡΡΡΡΡ ΠΠ°ΡΡΠΎΠ½Π°Π»Ρ-Π½ΠΈΠΉ Π³ΡΡΠ½ΠΈΡΠΈΠΉ ΡΠ½ΡΠ²Π΅ΡΡΠΈΡΠ΅Ρ (ΠΠΠ£). Π‘Π΅ΡΠ΅Π΄ Π²ΠΈΠ΄Π°ΡΠ½ΠΈΡ
Π²ΡΠ΅Π½ΠΈΡ
Ρ ΡΠ°Π»Π°Π½ΠΎΠ²ΠΈΡΠΈΡ
Π²ΠΈΠΊΠ»Π°-Π΄Π°ΡΡΠ², ΡΠΊΡ ΡΡΠ»Π°Π²ΠΈΠ»ΠΈ ΡΠ΅ΠΉ Π·Π°ΠΊΠ»Π°Π΄ ΠΎΡΠ²ΡΡΠΈ, β ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π½ΠΈΠΊΠΈ Π΄ΠΈΠ½Π°ΡΡΡΡ ΠΠ΅Π½Π΄ΡΠΈΡ
ΡΠ²ΡΡΠΊΠΈΡ
. ΠΠ²ΡΠΎΡΠΈ Π΄Π°Π½ΠΎΡ ΡΡΠ°ΡΡΡ Π²Π²Π°ΠΆΠ°ΡΡΡ, ΡΠΎ Π΄ΠΎΡΠ»ΡΠ΄ΠΆΠ΅Π½Π½Ρ Π°ΡΠΏΠ΅ΠΊΡΡΠ² ΡΡΡΠΎΡΡΡ Π³ΡΡΠ½ΠΈΡΠΎΡ Π½Π°ΡΠΊΠΈ ΡΠ° ΠΎΡΠ²ΡΡΠΈ Π½Π΅ΠΌΠΎΠΆΠ»ΠΈΠ²Π΅ Π±Π΅Π· Π²ΡΠ΄ΡΠ²ΠΎΡΠ΅Π½Π½Ρ ΡΠΎΡΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΏΠΎΡΡΡΠ΅ΡΡ ΡΡΠ΅Π½ΠΈΡ
ΡΠ° Π²ΠΈ-ΠΊΠ»Π°Π΄Π°ΡΡΠ²
ΠΠΈΠΊΡΠΎΠ΄Π²ΠΈΠ³Π°ΡΠ΅Π»Ρ-ΠΌΠ°Ρ ΠΎΠ²ΠΈΠΊ Π΄Π»Ρ ΠΌΠ°Π»ΠΎΠ³ΠΎ ΠΊΠΎΡΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π°ΠΏΠΏΠ°ΡΠ°ΡΠ°
ΠΡΠΏΡΡΠΊΠ½Π°Ρ ΠΊΠ²Π°Π»ΠΈΡΠΈΠΊΠ°ΡΠΈΠΎΠ½Π½Π°Ρ ΡΠ°Π±ΠΎΡΠ° ΡΠΎΡΡΠΎΠΈΡ ΠΈΠ· 120 Ρ. ΡΠ΅ΠΊΡΡΠΎΠ²ΠΎΠ³ΠΎ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Π°, 41 ΡΠΈΡΡΠ½ΠΊΠΎΠ², 8 ΡΠ°Π±Π»ΠΈΡ, 30 ΠΈΡΡΠΎΡΠ½ΠΈΠΊΠΎΠ² Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ, 5 Π»ΠΈΡΡΠΎΠ² Π³ΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»Π°.
ΠΠ»ΡΡΠ΅Π²ΡΠ΅ ΡΠ»ΠΎΠ²Π°: ΠΌΠ°Π»ΡΠΉ ΠΊΠΎΡΠΌΠΈΡΠ΅ΡΠΊΠΈΠΉ Π°ΠΏΠΏΠ°ΡΠ°Ρ, ΡΠΈΡΡΠ΅ΠΌΡ ΠΎΡΠΈΠ΅Π½ΡΠ°ΡΠΈΠΈ ΠΈ Π½Π°Π²ΠΈΠ³Π°ΡΠΈΠΈ, Π΄Π²ΠΈΠ³Π°ΡΠ΅Π»Ρ-ΠΌΠ°Ρ
ΠΎΠ²ΠΈΠΊ, Π±Π΅ΡΠΊΠΎΠ½ΡΠ°ΠΊΡΠ½ΡΠΉ Π΄Π²ΠΈΠ³Π°ΡΠ΅Π»Ρ ΠΏΠΎΡΡΠΎΡΠ½Π½ΠΎΠ³ΠΎ ΡΠΎΠΊΠ°, ΡΠΈΡΡΠ΅ΠΌΠ° ΡΠΏΡΠ°Π²Π»Π΅Π½ΠΈΡ Π±Π΅ΡΠΊΠΎΠ½ΡΠ°ΠΊΡΠ½ΡΠΌΠΈ Π΄Π²ΠΈΠ³Π°ΡΠ΅Π»ΡΠΌΠΈ ΠΏΠΎΡΡΠΎΡΠ½Π½ΠΎΠ³ΠΎ ΡΠΎΠΊΠ°, ΠΌΠΈΠΊΡΠΎΠΊΠΎΠ½ΡΡΠΎΠ»Π»Π΅Ρ, Π΄Π°ΡΡΠΈΠΊ ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΡ ΡΠΎΡΠΎΡΠ°, Π΄ΡΠ°ΠΉΠ²Π΅Ρ, ΡΠΈΠ»ΠΎΠ²ΡΠ΅ ΠΊΠ»ΡΡΠΈ, ΠΠΠ-ΡΠ΅Π³ΡΠ»ΡΡΠΎΡ.
ΠΠ±ΡΠ΅ΠΊΡΠΎΠΌ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΠ²Π»ΡΠ΅ΡΡΡ Π΄Π²ΠΈΠ³Π°ΡΠ΅Π»Ρ-ΠΌΠ°Ρ
ΠΎΠ²ΠΈΠΊ Π΄Π»Ρ ΠΌΠ°Π»ΠΎΠ³ΠΎ ΠΊΠΎΡΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π°ΠΏΠΏΠ°ΡΠ°ΡΠ°.
Π¦Π΅Π»Ρ ΡΠ°Π±ΠΎΡΡ β ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠ° ΡΠΈΡΡΠ΅ΠΌΡ ΡΠΏΡΠ°Π²Π»Π΅Π½ΠΈΡ Π΄Π²ΠΈΠ³Π°ΡΠ΅Π»Π΅ΠΌ-ΠΌΠ°Ρ
ΠΎΠ²ΠΈΠΊΠΎΠΌ Π΄Π»Ρ ΠΌΠ°Π»ΠΎΠ³ΠΎ ΠΊΠΎΡΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π°ΠΏΠΏΠ°ΡΠ°ΡΠ°, ΠΏΠΎΡΡΡΠΎΠ΅Π½Π½ΡΠΌ Π½Π° ΠΎΡΠ½ΠΎΠ²Π΅ Π±Π΅ΡΠΊΠΎΠ½ΡΠ°ΠΊΡΠ½ΠΎΠ³ΠΎ Π΄Π²ΠΈΠ³Π°ΡΠ΅Π»Ρ ΠΏΠΎΡΡΠΎΡΠ½Π½ΠΎΠ³ΠΎ ΡΠΎΠΊΠ°.
Π ΠΏΡΠΎΡΠ΅ΡΡΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈΡΡ: ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠ° ΡΠΈΡΡΠ΅ΠΌΡ ΡΠΏΡΠ°Π²Π»Π΅Π½ΠΈΡ Π΄Π²ΠΈΠ³Π°ΡΠ΅Π»Π΅ΠΌ-ΠΌΠ°Ρ
ΠΎΠ²ΠΈΠΊΠΎΠΌ ΠΏΡΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠΈ ΡΠΏΠ΅ΡΠΈΠ°Π»ΠΈΠ·ΠΈFinal qualifying work includes XX pages of textual material, XX pictures, XX tables, XX references, X graphic sheet material.
Keywords: small spacecraft, orientation and navigation system, motor-flywheel, brushless direct current motor, brushless DC motor control system, microcontroller, rotor position sensor, driver, power switch, PID-regulator.
The object of research is the motor-flywheel for small spacecraft.
Aim of the work β development of the motor-flywheel control system for small spacecraft, built on the basic of brushless DC motor.
In the process of research development of the motor-flywheel control system using specialized microchip and microcontroller, development of electric schematic diagram developed system, development of technological process assembly PCA, development of
Efficacy of long-term oral telmisartan treatment in cats with hypertension: Results of a prospective European clinical trial
BACKGROUND: Efficacy of telmisartan in treating hypertension (HT) in cats has not been largely investigated.
OBJECTIVE: Telmisartan oral solution effectively controls systolic arterial blood pressure (SABP) in hypertensive cats.
ANIMALS: Two-hundred eighty-five client-owned cats with systemic HT.
METHODS: Prospective, multicenter, placebo-controlled, randomized, double-blinded study. Hypertensive cats diagnosed with SABP β₯160βmmHg and β€200βmmHg without target-organ-damage were randomized (2β:β1 ratio) to receive 2βmg/kg telmisartan or placebo q24 PO. A 28-day efficacy phase was followed by a 120-day extended use phase. Efficacy was defined as significant difference in mean SABP reduction between telmisartan and placebo on Day 14 and group mean reduction in SABP of > 20 mmHg by telmisartan on Day 28 compared to baseline.
RESULTS: Two-hundred fifty-two cats completed the efficacy and 144 cats the extended use phases. Mean SABP reduction at Day 14 differed significantly between groups (P <β.001). Telmisartan reduced baseline SABP of 179βmmHg by 19.2 (95% confidence interval [CI]: 15.92-22.52) and 24.6 (95% CI: 21.11-28.14) mmHg at Days 14 and 28. The placebo group baseline SABP of 177βmmHg was reduced by 9.0 (95% CI: 5.30-12.80) and 11.4 (95% CI: 7.94-14.95) mmHg, respectively. Of note, 52% of telmisartan-treated cats had SABP <150βmmHg at Day 28. Mean SABP reduction by telmisartan in severe (β₯180βmmHg) and moderate HT (160-179βmmHg) was comparable and persistent over time.
CONCLUSIONS AND CLINICAL IMPORTANCE: Telmisartan solution (PO) was effective in reducing SABP in hypertensive cats with SABP β₯160βmmHg and β€200βmmHg
- β¦